Three drug-resistant pathogens come up over and over in documented Olympus endoscope outbreaks: CRE, MRSA, and Pseudomonas aeruginosa. They are not random infections. Each has been traced — in published outbreak investigations — to the same closed-channel scope design that hospitals cannot reliably disinfect.
If your culture report named one of these pathogens after an endoscopic procedure, the connection to a contaminated scope is documented science, not speculation. This page explains each pathogen in plain English — what it is, why it is hard to treat, and why scopes spread it.
A modern flexible endoscope — the kind used in colonoscopies, ERCP, bronchoscopies, and other internal exams — is one of the most complex reusable instruments in medicine. It contains long, narrow internal channels, a working tip with moving parts, and (in duodenoscopes) an "elevator" mechanism that bends to direct surgical tools. All of those parts touch the inside of a patient's body. All of them have to be cleaned and disinfected before the scope is used again.
The problem is that the FDA, scope manufacturers, and infection-control researchers have all confirmed the same thing: these scopes cannot be reliably disinfected by following the manufacturer's instructions. Bacteria can survive inside the closed channels. They can form sticky biofilms in the elevator mechanism. They can pass from one patient to the next, even in hospitals that follow every step of the cleaning protocol.
That design flaw is what makes drug-resistant pathogens — the kinds normally seen in ICU patients on heavy antibiotics — show up in outpatient endoscopy clinics. The scope itself becomes the bridge. The pathogens described on this page are the ones that have shown up most often in published outbreak investigations going back to 2012.
CRE is the pathogen at the center of every major Olympus duodenoscope outbreak the public has heard about — UCLA, Virginia Mason, Cedars-Sinai. The CDC has called CRE one of its highest-priority drug-resistance threats. When CRE turns up in an outpatient procedure clinic, the explanation is almost always a contaminated reusable scope.
CRE stands for Carbapenem-Resistant Enterobacteriaceae — a family of bacteria that has become resistant to carbapenems, a class of last-resort antibiotics. The most common species in the family are Klebsiella pneumoniae, Escherichia coli, and Enterobacter. They normally live in the gut. When they get into the bloodstream of a patient who cannot fight them off, they are very hard to clear.
Carbapenems are the antibiotics doctors reach for when the standard ones have failed. CRE has acquired enzymes — usually a gene called KPC or NDM — that destroy carbapenems before they can work. The CDC has reported that bloodstream infections with CRE carry mortality rates around 40 to 50 percent. Treatment usually requires combination therapy with older, more toxic antibiotics like colistin.
CRE infection symptoms depend on where the bacteria settle. In the bloodstream: fever, chills, low blood pressure, confusion. In the bile duct after ERCP: jaundice, severe abdominal pain, fever. In the urinary tract: burning, frequency, fever. The hallmark is that the infection does not respond to first-line antibiotics — the patient gets sicker on standard treatment, and the lab reports start using words like "carbapenem-resistant."
Every major published Olympus duodenoscope outbreak in the last decade has involved CRE or a closely related drug-resistant pathogen. UCLA, 2015: at least seven patients infected with CRE traced to two specific Olympus duodenoscopes. Virginia Mason, 2012–2014: 32 patients infected, 11 deaths, traced to ERCP scopes. Cedars-Sinai, 2015: at least four CRE patients traced to a single scope. The pattern keeps repeating because the underlying scope design has not fundamentally changed.
If your culture report names CRE, KPC, NDM, or "carbapenem-resistant" anything — and the timing fits a recent endoscopic procedure — the scope-source connection is well-documented in the medical literature.
Most people have heard of MRSA. It is the drug-resistant staph infection that has been making hospital headlines since the early 2000s. What is less well known is that MRSA also shows up in scope-related outbreaks — particularly bronchoscopes used in lung procedures — where the moist internal channels and biofilm-forming surfaces give it a place to hide between patients.
MRSA is a strain of Staphylococcus aureus that has become resistant to methicillin and most other beta-lactam antibiotics — the entire penicillin family. It is one of the oldest known antibiotic-resistant bacteria. The CDC tracks both hospital-associated MRSA (HA-MRSA), which tends to be the most aggressive, and community-associated MRSA. Scope-related MRSA infections are almost always the hospital-associated type.
Penicillin and its relatives normally kill staph by breaking open the bacterial cell wall. MRSA carries the mecA gene, which produces a modified target that those antibiotics cannot bind to. Doctors have to fall back on vancomycin or newer alternatives like linezolid — both more toxic, both not always sufficient. Severe MRSA bloodstream and lung infections still carry mortality rates around 15 to 25 percent in published series.
MRSA from a scope usually shows up as a serious lung infection (after bronchoscopy) or a bloodstream infection. Lung symptoms: high fever, cough with thick or bloody sputum, shortness of breath, chest pain. Bloodstream symptoms: persistent high fever, chills, low blood pressure, fast heart rate. Skin or wound MRSA — pus-filled abscesses — is more typical of community MRSA, not the scope-borne form.
MRSA produces biofilms — sticky communities of bacteria that adhere to surfaces and resist disinfection. The internal channels of a flexible scope are an ideal biofilm habitat: warm, moist, and rarely fully dried. Published bronchoscope outbreak investigations have documented MRSA pneumonia clusters traced to inadequately reprocessed scopes. The same closed-channel design that traps CRE traps MRSA.
Pseudomonas aeruginosa is the third pathogen that turns up consistently in scope-outbreak reports. It has a particular affinity for moist environments — sinks, water systems, the inner channels of inadequately dried endoscopes — and it is intrinsically resistant to many common antibiotics. Bronchoscope outbreaks in particular have repeatedly traced back to Pseudomonas contamination.
Pseudomonas aeruginosa is a gram-negative bacterium found in soil, water, and on plant surfaces. It is an opportunistic pathogen — meaning it does not usually cause illness in healthy people, but it can cause severe infections in patients whose defenses are down: those who are critically ill, immunocompromised, on ventilators, or who have just had an internal procedure that introduced bacteria past the body's normal barriers.
Pseudomonas has built-in resistance mechanisms that many other bacteria lack — efflux pumps that flush antibiotics out, low-permeability cell walls, and the ability to acquire resistance genes from other bacteria. It also forms tough biofilms. Treatment typically requires two-drug combinations at high doses. Multidrug-resistant strains — resistant to several antibiotic classes at once — are increasingly common and limit options further.
Pseudomonas symptoms depend on the organ system. Lung infection (most common after bronchoscopy): fever, cough, shortness of breath, often in a patient who was admitted for a different reason. Bloodstream: classic sepsis signs — high fever, low blood pressure, organ dysfunction. Urinary tract: burning, fever, sometimes blood in the urine. The lab tip-off is a culture that grows "Pseudomonas aeruginosa" with antibiotic-resistance flags.
Bronchoscope-associated Pseudomonas pneumonia outbreaks have been documented for decades and continue to surface in peer-reviewed reports. The pattern is consistent: a scope is reprocessed but not adequately dried, residual moisture in the internal channel allows Pseudomonas to grow overnight, and the next morning's first patient receives the contaminated scope. Olympus bronchoscopes have shown up in multiple published investigations of these clusters.
CRE, MRSA, and Pseudomonas are the headline three, but several other pathogens turn up in published scope-outbreak reports. If your culture named any of the bacteria below, the scope-source question is still worth asking.
Often the species behind a CRE outbreak. Drug-resistant Klebsiella appears regularly in duodenoscope investigations and in ICU bronchoscope clusters. The lab may report it separately from "CRE" if resistance testing is not yet complete.
A gram-negative pathogen the CDC ranks among the most dangerous drug-resistant bacteria. Multidrug-resistant Acinetobacter has been traced to bronchoscope and ICU equipment outbreaks. Bloodstream infections carry high mortality.
Extended-spectrum beta-lactamase E. coli is resistant to most penicillins and cephalosporins. It has been documented in duodenoscope outbreaks, especially after ERCP procedures, and may appear on culture reports before full carbapenem testing.
Resistant to vancomycin, the standard backup antibiotic. VRE has been linked to scope and ICU-equipment transmission. Bloodstream and abdominal infections after gastrointestinal procedures are the typical presentation.
In a scope-infection case, the pathogen on your culture report is not just a medical detail. It is evidence. The specific bacteria identified by your lab can directly support — or weaken — the connection between the procedure and the infection.
CRE, MRSA, Pseudomonas, Klebsiella, Acinetobacter, ESBL E. coli, and VRE all share a common feature that matters here: they are not the kind of bacteria a healthy person picks up at home. They are hospital-environment pathogens, frequently traced to medical equipment, and they appear in the published Olympus scope outbreak literature. When one of them shows up in a patient who was healthy enough to walk into an outpatient clinic for a routine endoscopic procedure, the timing and the pathogen tell a coherent story.
That coherence is what a careful case review looks for. Our team — including Herb Borroto, M.D., J.D. — reviews the procedure record, the timing of symptoms, the culture results, and the documented outbreak literature for that specific pathogen. The cleaner that story is, the stronger the case.
If your records show one of these pathogens after an endoscopic procedure, the 3-part qualification test is a good 2-minute starting point. The free case review takes it from there.
What patients ask most often about superbug infections after endoscopic procedures — and what the published medical evidence says.
A regular bacterial infection responds to first-line antibiotics — the patient improves within a few days of starting standard treatment. A drug-resistant or 'superbug' infection does not. The lab reports back that the bacteria are resistant to the drugs that were prescribed, and doctors have to switch to backup antibiotics that are often more toxic, more expensive, and less effective. The CRE, MRSA, and Pseudomonas pathogens described on this page are all examples of drug-resistant infections.
The pathogen tells the story of where the infection came from. Drug-resistant pathogens like CRE, multidrug-resistant Pseudomonas, and hospital-associated MRSA are not pathogens that healthy people pick up at home or in the community. They are environmental hospital pathogens, repeatedly traced to medical equipment in published outbreak investigations. When one of those bacteria shows up after an endoscopic procedure, the connection to the scope is supported by years of published medical literature.
Yes. Many patients never see their full culture report — the records are kept in the hospital's lab system rather than in the discharge paperwork. As part of a free case review, we request the full medical record, including the lab and microbiology data. If a drug-resistant pathogen was identified at any point, it will be in those records. You do not need to know the answer before contacting us.
It is rarely possible to prove a single source with absolute certainty — but the timing, pathogen, and procedure together make a strong case. An infection that appears 3 to 30 days after an endoscopic procedure, in a patient who was previously healthy, with a pathogen documented in the scope-outbreak literature, fits the pattern. Our medical-legal review focuses on whether all three pieces — timing, pathogen, procedure — line up.
That is a common explanation, especially when hospitals have not connected an individual case back to a possible scope source. Hospitals have access to FDA safety communications, recall notices, and outbreak investigations — but they often do not pass that information to patients. Many of the patients in published Olympus outbreak reports were never told the scope was suspected. The fact that your doctor did not raise the question does not mean the answer is no. It means the question was never asked.
Every factual claim on this page is supported by a verifiable public source. Click any source below to read the original.
Browse the full library of contaminated endoscope and Olympus scope investigation pages.
Start here — overview of contaminated endoscope litigation.
How design flaws turn scopes into superbug carriers.
Colonoscopy, ERCP, bronchoscopy, upper endoscopy — what's at risk.
Timeline of FDA recalls, warnings, and import alerts.
CRE, MDRO, sepsis warning signs to watch for.
The closed-channel elevator that resists sterilization.
Duodenoscope-linked outbreaks and ERCP claims.
When routine screenings cause hospital-acquired infections.
Cleaning shortcuts that put patients at risk.
Find out in 60 seconds if you have a case.
Latest FDA actions, MDL updates, and case news.
What the June 2025 FDA Olympus import alert means for patients.
Where Olympus scope cases stand: no MDL yet, individual filings, deadline pressure.
How to find out which scope was used on you and what records to request.
If your culture report names CRE, MRSA, Pseudomonas, or any of the other drug-resistant bacteria covered on this page — and you had an endoscopic procedure in the weeks before — the connection is documented science. A free case review takes about 15 minutes and costs nothing. No Fees Unless We Recover Money for You.
